// App-Quantinova.ai

OC 21.5 : Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement estimated through propensity scoring

Researchers

Presenter

  • H. Liu

Principal Investigators

  • C. Hawes

  • C. Hsu

  • X. Yang

  • T. Robinson

  • D. Hinds

Medical Centers

  • BioMarin Pharmaceutical Inc., Novato, United States

  • BioMarin Europe Ltd, London, England, United Kingdom

  • Delta Hat, Nottingham, England, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • NCT03370913

Sponsors

  • BioMarin Pharmaceutical Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved